+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market - Global Forecast 2026-2032- Product Image
Ankylosing Spondylitis Market - Global Forecast 2026-2032- Product Image
Sale

Ankylosing Spondylitis Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5292911
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ankylosing Spondylitis Market is projected to reach USD 6.68 Billion in 2026. It is expected to continue growing at a CAGR of 6.85%, reaching USD 9.98 Billion by 2032.

Ankylosing spondylitis, commonly discussed within the broader axial spondyloarthritis spectrum, is a chronic immune-mediated inflammatory disease that primarily affects the sacroiliac joints and spine. The market is shaped by earlier diagnosis, wider use of biologic and targeted synthetic therapies, and rising demand for long-term control of inflammatory back pain, stiffness, fatigue, mobility loss, structural progression, and extra-articular manifestations such as acute anterior uveitis, psoriasis, and inflammatory bowel disease.

Verified clinical literature consistently shows that axial spondyloarthritis affects a measurable share of the adult population globally, with prevalence varying by geography, HLA-B27 frequency, diagnostic access, and case definition. Growth opportunities are concentrated in MRI-enabled diagnosis, rheumatology referral pathways, TNF inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars, patient support programs, treat-to-target care, and evidence-based digital monitoring.

Transformative Shifts in the Ankylosing Spondylitis Landscape

The ankylosing spondylitis landscape is shifting from late-stage radiographic recognition toward earlier identification of inflammatory back pain and non-radiographic axial spondyloarthritis. Adoption of ASAS classification concepts, MRI of sacroiliac joints, HLA-B27 testing where clinically appropriate, C-reactive protein assessment, and standardized disease activity tools such as BASDAI and ASDAS is changing how clinicians evaluate patients before structural damage becomes visible on X-ray.

Treatment pathways are also transforming. NSAIDs remain foundational for symptom control, exercise and physiotherapy remain core non-pharmacologic interventions, and biologics and targeted synthetic DMARDs are increasingly used for patients with persistently active disease. Biosimilar competition is improving affordability in many markets, and payers are requiring clearer evidence of response, persistence, safety, functional improvement, and quality-of-life gains.

Cumulative Impact of Artificial Intelligence in Ankylosing Spondylitis Care

Artificial intelligence is accumulating influence across the ankylosing spondylitis care pathway rather than replacing clinical judgment. AI-supported imaging tools are being evaluated to improve detection of sacroiliitis, quantify inflammatory and structural lesions on MRI, support radiographic scoring, and reduce variability in interpretation, which is especially important where musculoskeletal radiology expertise is limited.

AI also supports risk stratification, real-world evidence generation, patient-reported outcome analysis, and treatment adherence monitoring. When integrated with electronic health records, claims data, laboratory markers, imaging repositories, and wearable mobility signals, AI can help identify delayed referrals, predict flare patterns, support pharmacovigilance, and guide value-based decisions while maintaining clinician oversight, data privacy, algorithm transparency, and regulatory compliance.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America and Europe remain highly influential ankylosing spondylitis markets due to established rheumatology networks, broad biologic access, guideline-driven treatment, active clinical research, and strong real-world evidence infrastructure. The United States, Canada, the United Kingdom, Germany, France, Italy, and Spain show continued demand for advanced therapies, while Europe benefits from biosimilar adoption, pharmacovigilance systems, centralized or national health technology assessment processes, and structured reimbursement pathways.

Asia-Pacific is expanding through rising diagnosis in China, Japan, India, South Korea, and Australia, supported by larger patient pools, improving specialty care, growing MRI availability, and increasing awareness of inflammatory back pain. Latin America shows opportunity in Brazil and Mexico but faces uneven reimbursement, public-private access gaps, and diagnostic delays. The Middle East, led by Gulf health systems, is investing in tertiary specialty care, digital health infrastructure, and access to advanced therapies, while Africa remains constrained by limited rheumatology workforce, delayed diagnosis, restricted imaging availability, and affordability barriers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Across ASEAN, improving hospital infrastructure, expanding private healthcare networks, and broader access to rheumatology are gradually strengthening ankylosing spondylitis diagnosis, although affordability, specialist density, and reimbursement consistency remain limiting factors. The GCC is advancing specialty care through high health expenditure, biologic availability, national health transformation programs, and investment in digital health platforms, particularly in urban tertiary centers where complex immune-mediated diseases are increasingly managed through specialist pathways.

The European Union remains a benchmark for guideline adoption, pharmacovigilance, cross-border regulatory consistency, health technology assessment, and biosimilar integration. BRICS markets combine large patient potential with varied reimbursement maturity, local manufacturing priorities, and uneven access to MRI and biologics, making access strategy country-specific. G7 markets lead in innovation uptake, clinical evidence generation, real-world data use, and payer scrutiny, while NATO-aligned countries often overlap with advanced procurement systems, regulatory harmonization, resilient medicine supply-chain priorities, and established standards for biologic and biosimilar governance.

Key Country Insights for Ankylosing Spondylitis

The United States leads in branded biologic and targeted therapy uptake, supported by specialist care, insurance-driven formulary management, patient assistance programs, and active clinical research, while Canada emphasizes evidence-based reimbursement, provincial access decisions, and equitable care delivery. Mexico and Brazil show growing need for biologics and biosimilars, but coverage variability, public system capacity, and affordability shape adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on national health systems, clinical guidelines, health technology assessment, and biosimilar-driven cost management; Russia maintains demand but faces access, reimbursement, and supply-chain complexities.

China and India represent high-volume opportunities as diagnosis improves, rheumatology capacity expands, and biosimilar availability increases, although affordability and regional care gaps persist. Japan, South Korea, and Australia benefit from mature specialty systems, structured reimbursement, established rheumatology practice standards, and consistent use of evidence-based treatment algorithms. Across these countries, the most important differentiators are early referral from primary care, access to MRI, payer acceptance of advanced therapies, treatment persistence, and long-term monitoring of safety and functional outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize early diagnosis programs, rheumatologist education, and referral tools that help distinguish inflammatory back pain from mechanical back pain. Partnerships with imaging centers, primary care networks, orthopedics, ophthalmology, gastroenterology, dermatology, and patient advocacy groups can reduce diagnostic delay, support recognition of extra-articular disease, and improve treatment initiation.

Commercial strategies should align biologic, biosimilar, and JAK inhibitor positioning with payer evidence needs, including sustained response, safety, adherence, functional improvement, work productivity, and quality-of-life outcomes. Organizations should invest in real-world evidence, AI-enabled patient identification, digital monitoring, pharmacovigilance, and market-specific access models that address reimbursement, affordability, treatment continuity, and responsible use of advanced therapies.

Research Methodology

This executive summary is based on triangulation of peer-reviewed rheumatology literature, regulatory approvals, clinical practice guidelines, health technology assessment patterns, epidemiology publications, payer policy trends, and publicly available information from recognized health authorities. The analysis prioritizes validated evidence from rheumatology associations, regulatory agencies, clinical trial registries, pharmacovigilance sources, epidemiological reviews, and published real-world studies.

The methodology combines qualitative assessment of treatment pathways with market-facing evaluation of access, reimbursement, regional infrastructure, competitive intensity, biosimilar adoption, diagnostic capability, and technology adoption. Insights are presented conservatively, avoiding unverified forecasts and emphasizing data-backed trends relevant to strategic planning in ankylosing spondylitis and axial spondyloarthritis.

Conclusion

The ankylosing spondylitis market is moving toward earlier diagnosis, more personalized therapy selection, and stronger evidence requirements from payers and health systems. Biologics, biosimilars, targeted synthetic therapies, imaging innovation, structured disease activity measurement, and AI-supported care coordination are redefining how stakeholders address chronic inflammation, functional limitation, and long-term disease burden.

Future market leadership will depend on balancing innovation with access. Organizations that combine clinical credibility, real-world evidence, patient-centered support, responsible digital integration, and region-specific affordability strategies will be best positioned to improve outcomes and capture sustainable growth in the evolving axial spondyloarthritis ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Ankylosing Spondylitis Market, by Therapy Type
7.1. Introduction
7.2. Pharmacological
7.2.1. NSAIDs
7.2.2. Biologics
7.2.3. DMARDs
7.3. Non-Pharmacological
7.3.1. Physiotherapy
7.3.2. Postural Training
7.4. Surgical
7.4.1. Hip Replacement
7.4.2. Spinal Osteotomy
8. Ankylosing Spondylitis Market, by Administration Route
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous Infusion
8.2.2. Subcutaneous Injection
8.3. Intravenous
8.4. Oral
8.4.1. Capsules
8.4.2. Tablets
9. Ankylosing Spondylitis Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Ankylosing Spondylitis Market, by Disease Classification
10.1. Introduction
10.2. Axial Spondyloarthritis (axSpA)
10.3. Peripheral Spondyloarthritis
11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Homecare Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Ankylosing Spondylitis Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Ankylosing Spondylitis Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Ankylosing Spondylitis Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Biothera Pharmaceuticals, Inc.
16.4. Boehringer Ingelheim International GmbH
16.5. Bristol-Myers Squibb Company
16.6. Celgene Corporation
16.7. Celltrion Healthcare Co.,Ltd.
16.8. Eisai Co., Ltd
16.9. Eli Lilly and Company
16.10. Gilead Sciences, Inc.
16.11. GlaxoSmithKline PLC
16.12. Hetero Drugs Limited
16.13. Johnson & Johnson Services Inc.
16.14. Merck & Co. Inc.
16.15. Mylab Discovery Solutions Pvt. Ltd.
16.16. Novartis AG
16.17. Pfizer, Inc.
16.18. Reliance Life Sciences
16.19. Samsung Bioepis Co., Ltd.
16.20. Sandoz International GmbH
16.21. Shanghai Pharmaceuticals Holding Co., Ltd.
16.22. Takeda Pharmaceutical Company Limited
16.23. Trinity Biotech PLC
16.24. UCB, Inc.
16.25. Xian Janssen Pharmaceutical Ltd
List of Figures
FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DMARDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DMARDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DMARDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PHYSIOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POSTURAL TRAINING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POSTURAL TRAINING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POSTURAL TRAINING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SURGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SURGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SURGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HIP REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL HIP REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HIP REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SPINAL OSTEOTOMY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PERIPHERAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HOMECARE CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOMECARE CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOMECARE CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 97. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 98. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 100. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 101. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 102. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 128. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 130. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 131. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 132. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 133. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 134. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 135. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 136. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 137. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 138. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 153. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 154. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 155. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 156. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 157. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 158. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 159. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 160. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 161. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 164. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 165. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 166. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 167. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 168. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 169. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 170. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 171. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 172. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 176. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 177. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 178. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 179. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 180. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 181. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 182. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 183. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 197. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 198. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 199. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 200. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 201. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 202. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 203. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 204. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 205. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 208. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 209. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 210. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 211. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 212. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 213. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 214. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 215. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 216. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 218. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 220. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 221. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 222. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 223. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 224. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 225. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 226. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 227. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 228. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 242. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 243. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 244. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 245. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 246. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 248. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 249. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 250. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 253. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 254. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 255. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 256. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 257. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 258. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 259. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 261. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 265. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 266. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 267. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 271. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 272. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 298. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 299. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 300. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 302. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 303. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 304. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 305. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 319. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 320. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 321. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 322. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 323. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 324. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 325. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 326. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 327. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 329. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 330. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 331. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 332. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 333. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 334. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 335. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 336. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 337. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 338. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 341. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 342. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY NON-PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 343. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SURGICAL, 2017-2032 (USD MILLION)
TABLE 344. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 345. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 346. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 347. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 348. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DISEASE CLASSIFICATION, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 350. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 353. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Biothera Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Drugs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Trinity Biotech PLC
  • UCB, Inc.
  • Xian Janssen Pharmaceutical Ltd

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.98 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Ankylosing Spondylitis Market Forecast to 2033 - Product Image

Ankylosing Spondylitis Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Ankylosing Spondylitis Market Report 2026 - Product Image

Ankylosing Spondylitis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Ankylosing Spondylitis - Global Strategic Business Report - Product Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) Market - Global Strategic Business Report - Product Image

Axial Spondyloarthritis (AXSPA) Market - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Ankylosing Spondylitis (Bekhterev's Disease) Epidemiology Forecast 2026-2035 - Product Image

Ankylosing Spondylitis (Bekhterev's Disease) Epidemiology Forecast 2026-2035

  • Report
  • 150 Pages
  • Global
From

About the Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.